Main Post

The study of a drug's absorption, distribution, metabolism, and excretion by the body is known as pharmacokinetics. Pharmacodynamics is the study of a drug's physiological effects. (Forth et al, 2023)

The two main types of anxiolytic drugs used to treat GAD are those that work on the central nervous system (CNS) and those that work on the peripheral nervous system (PNS). Beta-blockers and benzodiazepines are examples of CNS-acting medications. Alpha-blockers and anticholinergics are examples of PNS-acting medications.

The most frequently given group of medications for anxiety disorders is called benzodiazepines. They function by attaching to GABA receptors, which boosts GABA's activity as a neurotransmitter. The brain is consequently calmed by this. Although benzodiazepines are frequently successful in treating anxiety, they can also make you feel sleepy, lightheaded, and confused.

Beta-blockers can be useful for reducing anxiety in addition to their usual usage for treating cardiac problems. They function by preventing the hormone adrenaline from doing its job, which helps lessen the physical signs of anxiety like perspiration and a beating heart. Although beta-blockers are less likely to have side effects, they are less effective than benzodiazepines for treating anxiety (Forth et al, 2023).

Anticholinergics are frequently used to treat digestive disorders, but they are also useful for reducing anxiety. They function by preventing the neurotransmitter acetylcholine from doing its job, which helps lessen the physical signs of anxiety like perspiration and a beating heart. Although anticholinergics are less likely to have side effects, they are less effective than benzodiazepines for treating anxiety.

Although alpha-blockers are frequently used to treat hypertension, they can also be helpful in the management of anxiety. They function by preventing the neurotransmitter norepinephrine from doing its job, which helps lessen the physical signs of anxiety like perspiration and a beating heart. Although alpha-blockers are less likely to have side effects, they are less effective than benzodiazepines for treating anxiety.

Medication is the most popular form of treatment for GAD. GAD can be treated with a variety of medications, including benzodiazepines, beta-blockers, anticholinergics, and alpha-blockers.

The most frequently given group of medications for anxiety disorders is called benzodiazepines. They function by attaching to GABA receptors, which boosts GABA's activity as a neurotransmitter. The brain is consequently calmed by this. Although benzodiazepines are frequently successful in treating anxiety, they can also make you feel sleepy, lightheaded, and confused.

Beta-blockers can be useful for reducing anxiety in addition to their usual usage for treating cardiac problems. They function by preventing the hormone adrenaline from doing its job, which helps lessen the physical signs of anxiety like perspiration and a beating heart. Although beta-blockers are less likely to have side effects, they are less effective than benzodiazepines for treating anxiety.

Anticholinergics are frequently used to treat digestive disorders, but they are also useful for reducing anxiety. They function by preventing the neurotransmitter acetylcholine from doing its job, which helps lessen the physical signs of anxiety like perspiration and a beating heart. Although anticholinergics are less likely to have side effects, they are less effective than benzodiazepines for treating anxiety (Forth et al, 2023)

Although alpha-blockers are frequently used to treat hypertension, they can also be helpful in the management of anxiety. They function by preventing the neurotransmitter norepinephrine from doing its job, which helps lessen the physical signs of anxiety like perspiration and a beating heart (van der Koog, 2022). Although alpha-blockers are less likely to have side effects, they are less effective than benzodiazepines for treating anxiety.

Benzodiazepines, such Xanax or Ativan, are frequently the most efficient treatment for GAD. However, because of their potential for adverse effects, benzodiazepines are not always the ideal choice. Beta-blockers or alpha-blockers may be preferable if side effects are a concern.

The quick start of action and effectiveness of benzodiazepines in reducing the symptoms of anxiety are well established. However, especially in patients with a history of substance abuse, they have a high potential for dependence and abuse. In this instance, it might be required to modify the dosage of benzodiazepines due to the patient's chronic kidney disease in order to prevent drug buildup and potential toxicity (Mauvais-Jarvis et al, 2021)

Due to their effectiveness and tolerability, SSRIs and SNRIs are regarded as first-line therapies for GAD. These drugs function by raising the brain's serotonin and/or norepinephrine levels, which aid in mood regulation and anxiety reduction. Compared to benzodiazepines, they start working more slowly and often take several weeks of treatment to fully exert their therapeutic effects. They do not, however, pose the same dangers of abuse and dependence as benzodiazepines. In this situation, SSRIs or SNRIs may be chosen over benzodiazepines due to their decreased risk for accumulation and toxicity given the patient's history of chronic kidney illness. (Forth et al, 2023)

It's crucial to take the requirements and reactions of each patient into account when evaluating various treatment alternatives. It is important to consider a variety of variables, including genetic variants, gender differences, ethnicity, age, behavior, and underlying pathophysiological alterations. Starting with a lower initial dose and gradually increasing it based on the patient's response and tolerability may be part of a tailored care plan (van der Koog, 2022). To obtain the best possible treatment outcomes, careful side effect and therapeutic efficacy monitoring is necessary

Reference

Forth, E., Buehner, B., Storer, A., Sgarbossa, C., Milev, R., & Chinna Meyyappan, A. (2023). Systematic review of probiotics as an adjuvant treatment for psychiatric disorders. Frontier in behavioral neuroscience 17, 11113491.

Juif, P. E., Dingemanse, J., Winkle, P., & Ufer, M. (2021). Pharmacokinetics and Pharmacodynamics of Cenerimod, A Selective S1P1R Modulator, Are Not Affected by Ethnicity in Healthy Asian and White Subjects.ClicnicaTransitional Science(1), 143-147

Mauvais-Jarvis, F., Berthold, H. K., Campesi, I., Carrero, J. J., Dhakal, S., Franconi, F., … & Rubin, J. B. (2021). Sex-and gender-based pharmacological response to drugs.Phamacological review, 2), 730-76

van der Koog, L., Gandek, T. B., & Nagelkerke, A. (2022). Liposomes and extracellular vesicles as drug delivery systems: A comparison of composition, pharmacokinetics, and functionalization. Advance healthcare material 11(5), 2100639.